Dr. Christopher Klebanoff is a Principal Investigator and Attending Physician at the Memorial Sloan Kettering Cancer Center. His research focuses on cell-based cancer immunotherapies, T cell receptors, and the therapeutic targeting of shared cancer neoantigens. Using single-cell sequencing, biophysical measurements of T cell receptor affinity, genetic engineering, and structural immunobiology, the Klebanoff lab aims to adapt adoptive T cell transfer for advanced solid tumors.
Featured Products and Resources:
The Immunology Science Round Up
Dual Targeting of Tregs – A CTLA-4 antibody combined with a signal regulatory protein modulates both “eat me” and “do not eat me” signals to deplete regulatory T cells in the tumor microenvironment.
A Cell-Free Assay for SARS-CoV-2 Neutralizing Antibodies – Researchers developed a multiplex assay to assess neutralizing antibodies to SARS-CoV-2 variants of concern in convalescent plasma.
T Cells and Oral Vaccines in Environmental Enteric Dysfunction – Scientists developed a mouse model for environmental enteric dysfunction and found impaired CD4+ T cell responses in the small intestine, which reduced oral vaccine efficacy.
Vertical Transfer of Maternal Immune Cells – Maternal microchimeric cells promote fetal immune development and are linked to a lower number of respiratory infections in early life.
Photo Reference: Courtesy of Dr. Christopher Klebanoff